Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer Gene Ther. 2011 Nov 25;19(3):192–201. doi: 10.1038/cgt.2011.77

Figure 5. Viral pathogenecity in athymic nude mice.

Figure 5

(a) Athymic mice were injected with vJS6 or vFasL intraperitoneally (i.p.) at a dose of 1.0 × 107 pfu/mouse, or PBS (n = 10 each). Median survival of the mice treated with vJS6 was 15 days while that of the mice with vFasL was 120 days (P < 0.00001 by log rank test). (b) Recovery of viruses on day 7 from normal tissues in non-tumor-bearing nude mice. Compared to vJS6, vFasL showed a significant decrease in viral titers from normal tissues at day 7 (p<0.02). (c) Viral titers of vJS6 and vFasL on days 3, 4, 5 in bilateral MC38 and B16 flank tumors. The virus vFasL showed a faster clearance in MC38 cancers even at day 3 compared to vJS6. vFasL persisted in FasR− B16 cancer like vJS6 virus, even though the titers are decreased on day 5.